673 related articles for article (PubMed ID: 25774903)
1. Fingolimod prevents blood-brain barrier disruption induced by the sera from patients with multiple sclerosis.
Nishihara H; Shimizu F; Sano Y; Takeshita Y; Maeda T; Abe M; Koga M; Kanda T
PLoS One; 2015; 10(3):e0121488. PubMed ID: 25774903
[TBL] [Abstract][Full Text] [Related]
2. Sera from remitting and secondary progressive multiple sclerosis patients disrupt the blood-brain barrier.
Shimizu F; Tasaki A; Sano Y; Ju M; Nishihara H; Oishi M; Koga M; Kawai M; Kanda T
PLoS One; 2014; 9(3):e92872. PubMed ID: 24686948
[TBL] [Abstract][Full Text] [Related]
3. Autocrine MMP-2/9 secretion increases the BBB permeability in neuromyelitis optica.
Tasaki A; Shimizu F; Sano Y; Fujisawa M; Takahashi T; Haruki H; Abe M; Koga M; Kanda T
J Neurol Neurosurg Psychiatry; 2014 Apr; 85(4):419-30. PubMed ID: 24259591
[TBL] [Abstract][Full Text] [Related]
4. Fingolimod attenuates ceramide-induced blood-brain barrier dysfunction in multiple sclerosis by targeting reactive astrocytes.
van Doorn R; Nijland PG; Dekker N; Witte ME; Lopes-Pinheiro MA; van het Hof B; Kooij G; Reijerkerk A; Dijkstra C; van van der Valk P; van Horssen J; de Vries HE
Acta Neuropathol; 2012 Sep; 124(3):397-410. PubMed ID: 22810490
[TBL] [Abstract][Full Text] [Related]
5. Fingolimod promotes blood-nerve barrier properties in vitro.
Nishihara H; Maeda T; Sano Y; Ueno M; Okamoto N; Takeshita Y; Shimizu F; Koga M; Kanda T
Brain Behav; 2018 Apr; 8(4):e00924. PubMed ID: 29670818
[TBL] [Abstract][Full Text] [Related]
6. Fingolimod (FTY720-P) Does Not Stabilize the Blood-Brain Barrier under Inflammatory Conditions in an in Vitro Model.
Schuhmann MK; Bittner S; Meuth SG; Kleinschnitz C; Fluri F
Int J Mol Sci; 2015 Dec; 16(12):29454-66. PubMed ID: 26690412
[TBL] [Abstract][Full Text] [Related]
7. Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis.
Chun J; Hartung HP
Clin Neuropharmacol; 2010; 33(2):91-101. PubMed ID: 20061941
[TBL] [Abstract][Full Text] [Related]
8. [Fingolimod therapy in multiple sclerosis--the issue of the pathomechanism].
Tar L; Vécsei L
Ideggyogy Sz; 2012 Mar; 65(3-4):83-100. PubMed ID: 23136726
[TBL] [Abstract][Full Text] [Related]
9. Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis.
Mehling M; Johnson TA; Antel J; Kappos L; Bar-Or A
Neurology; 2011 Feb; 76(8 Suppl 3):S20-7. PubMed ID: 21339487
[TBL] [Abstract][Full Text] [Related]
10. Glucocorticoid effects on endothelial barrier function in the murine brain endothelial cell line cEND incubated with sera from patients with multiple sclerosis.
Blecharz KG; Haghikia A; Stasiolek M; Kruse N; Drenckhahn D; Gold R; Roewer N; Chan A; Förster CY
Mult Scler; 2010 Mar; 16(3):293-302. PubMed ID: 20203147
[TBL] [Abstract][Full Text] [Related]
11. Sphingosine 1-phosphate signaling at the blood-brain barrier.
Prager B; Spampinato SF; Ransohoff RM
Trends Mol Med; 2015 Jun; 21(6):354-63. PubMed ID: 25939882
[TBL] [Abstract][Full Text] [Related]
12. Central nervous system-directed effects of FTY720 (fingolimod).
Miron VE; Schubart A; Antel JP
J Neurol Sci; 2008 Nov; 274(1-2):13-7. PubMed ID: 18678377
[TBL] [Abstract][Full Text] [Related]
13. Sphingosine 1 Phosphate at the Blood Brain Barrier: Can the Modulation of S1P Receptor 1 Influence the Response of Endothelial Cells and Astrocytes to Inflammatory Stimuli?
Spampinato SF; Obermeier B; Cotleur A; Love A; Takeshita Y; Sano Y; Kanda T; Ransohoff RM
PLoS One; 2015; 10(7):e0133392. PubMed ID: 26197437
[TBL] [Abstract][Full Text] [Related]
14. Differential effects of fingolimod (FTY720) on immune cells in the CSF and blood of patients with MS.
Kowarik MC; Pellkofer HL; Cepok S; Korn T; Kümpfel T; Buck D; Hohlfeld R; Berthele A; Hemmer B
Neurology; 2011 Apr; 76(14):1214-21. PubMed ID: 21464424
[TBL] [Abstract][Full Text] [Related]
15. Fingolimod in multiple sclerosis: mechanisms of action and clinical efficacy.
Ingwersen J; Aktas O; Kuery P; Kieseier B; Boyko A; Hartung HP
Clin Immunol; 2012 Jan; 142(1):15-24. PubMed ID: 21669553
[TBL] [Abstract][Full Text] [Related]
16. [Basic mechanisms of action of fingolimod in relation to multiple sclerosis].
García-Merino JA; Sánchez AJ
Rev Neurol; 2012 Jul; 55(1):31-7. PubMed ID: 22718407
[TBL] [Abstract][Full Text] [Related]
17. Investigation of immune and CNS-mediated effects of fingolimod in the focal delayed-type hypersensitivity multiple sclerosis model.
Anthony DC; Sibson NR; Losey P; Meier DP; Leppert D
Neuropharmacology; 2014 Apr; 79():534-41. PubMed ID: 24412675
[TBL] [Abstract][Full Text] [Related]
18. Fingolimod may support neuroprotection via blockade of astrocyte nitric oxide.
Colombo E; Di Dario M; Capitolo E; Chaabane L; Newcombe J; Martino G; Farina C
Ann Neurol; 2014 Sep; 76(3):325-37. PubMed ID: 25043204
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis.
Cohen JA; Chun J
Ann Neurol; 2011 May; 69(5):759-77. PubMed ID: 21520239
[TBL] [Abstract][Full Text] [Related]
20. Brain sphingosine-1-phosphate receptors: implication for FTY720 in the treatment of multiple sclerosis.
Dev KK; Mullershausen F; Mattes H; Kuhn RR; Bilbe G; Hoyer D; Mir A
Pharmacol Ther; 2008 Jan; 117(1):77-93. PubMed ID: 17961662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]